Quantum BioPharma Hits 50% Enrollment in PET Imaging Study with Strong MS Lesion Signals
Quantum BioPharma has enrolled half of participants in its Massachusetts General Hospital imaging study using the [¹⁸F]3F4AP PET tracer to assess demyelinated neurons. Early scans reveal strong signals in acute MS lesions and gray matter, bolstering the case for accelerating its Lucid-MS PAD2 inhibitor into Phase 2 trials.
1. Midpoint Enrollment Achieved
Quantum BioPharma enrolled 50% of targeted participants in its collaborative PET imaging study with Massachusetts General Hospital, validating the study protocol and patient recruitment strategy.
2. Promising Preliminary Imaging Readouts
Initial scans using the [¹⁸F]3F4AP tracer on advanced PET/MR and total-body PET platforms displayed robust uptake in acute MS lesions and detected potential gray matter involvement, indicating high sensitivity for demyelination.
3. Implications for Lucid-MS Development
These early biomarker readouts support the planned Phase 2 trial of Lucid-MS by offering a quantitative endpoint for assessing myelin preservation and regeneration via PAD2 inhibition, potentially accelerating the therapy’s clinical advancement.